You are here:

Esomeprazole (Nexium®)


Following a full submission.

Intravenous esomeprazole (Nexium IV®) is accepted for use within NHS Scotland for the treatment of gastroesophageal reflux disease in patients with esophagitis and/or severe symptoms of reflux as an alternative to oral therapy when oral intake is not appropriate.

Intravenous esomeprazole seems to be as effective as oral esomeprazole in terms of gastric acid suppression and healing of erosive oesophagitis. However comparisons with other IV proton pump inhibitors are restricted to pre-clinical studies. Esomeprazole has similar acquisition costs to other IV proton pump inhibitors.

Drug Details

Drug Name: Esomeprazole (Nexium®)
SMC Drug ID: 124/04
Manufacturer: AstraZeneca UK Ltd
Indication: Gastroesophageal reflux
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 October 2004